References
- [1] Aldawsari SF, Velazquez-Martinez CA. 3,4’,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency, The Journal of New Anticancer Agents-Springer Science + Business Media New York 2015; doi: 10.1007/s10637-015-0222-x; Published online: 28.02.2015.
- [2] Androutsopoulos VP, Ruparelia KC, Papakyriakou A, Filippakis H, TsatsakisAM, Spandidos DA. Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency, Eur. J. Med. Chem. 2011; 46 (6): 2586-95.
- [3] Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stiva la LA, Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4’-trimethoxystibene, Mol. Pharmcol. 2005; 67 (5): 1451-9.
- [4] Berbee JF, Wong MC, Wang Y, van der Hoorn JW, Khedoe PP, Dźwieku JB, Mol IM, Hiemstra PS, Tsikas D, Romijn JA. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice, J.Nutr.Biochem. 2013; 24 (8): 1423-30.
- [5] Berta GN, Salamone P., Sprio AE, Di Scipio F., Marinos LM, Sapino S., Carlotti ME, Cavalli R., Di Carlo F. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA) - induced oral carcinogenesis in hamster cheekpouch by topical application of resveratrol complexed with 2-hydroxypropyl-betacyclodextrin, Oral Oncol. 2010; 46 (1): 42-8.
- [6] Bertelli AA, Das DK. Gr apes, wines, r esver at r ol , and heart healt h, J. Cardiovasc. Pharmacol. 2009; 54: 468-476.
- [7] Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C. Antiproliferative activity of methylated analogues of E- and Z-resveratrol., Z. Naturforsch C. 2007; 62 (3-4): 189-95.
- [8] Cardile V, Lombardo L, Spatafora C, Tringali C. Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues, Bioorganic Chemistry. 2005; 33 (1): 22-33.
- [9] Chang TK, Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5, Can J. Physiol. Pharmacol. 2001; 79 (3): 220-6.
- [10] Cichocki M, Baer-Dubowska W, Wierzchowski M, Murias M, Jodynis-Liebert J. 3,4,5,4’-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF-ĸB, AP-1, and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen, Mol Cell Biochem. 2014; 391 (1-2): 27-35.
- [11] Colin D, Gimazane A, Lizard G., Izard JC, Solary E, Latruffe N, Delmas D. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5-fluorouracil sensitivity in human derived colon cancer cells, Int. J. Cancer. 2009; 124 (12): 2780-8.
- [12] Cucciolla V, Borriello O, Oliva A, Galletti P, Zappia V, Ragione FD. Resveratrol:From Basic Science to the Clinic, Cell Cycle 2007; 6 (20): 2495-2510.
- [13] DEAK M, FALK H. On the chemistry of resveratrol diastereomers, Monat für Chem. 2003; 134: 883-888.
- [14] Deng YH, Alex D, Huang HQ, Wang N, Yu N, Wang YT, Leung GP, Lee SM. Inhibit ion of TNF-α- mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4’-trimethoxystilbene, Phytother. Res. 2011; 25 (3): 451-7.
- [15] Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer, Drug Discover Today. 2010; 15 (17-18): 757-765.
- [16] Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects, Clin. Biochem. 2003; 36: 79-87.
- [17] Harikumar KB, Aggarwal BB. Resver atrol: a multitargeted agent for age-associated chronic diseases, Cell Cycle. 2008; 7 (8): 1020-1037.
- [18] Juan ME, Pilar Vinardell M, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful, Journal of Nutrition 2002; 132 (2): 257-260.
- [19] Kang SY, Lee JK, Choi O, Young Kim C, Jang JH, Hwang BY, Hong YS. Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E.coli, BMC Biotechnology, 14: 67; Published online 17.07.2014; doi:10.1186/1472-6750-14-6.
- [20] Kopeć A, Piątkowska E, Leszczyńska T, Bieżanowska-Kopeć R. Prozdrowotne właściwości resweratrolu, Nauka Technologia Jakość 2011; 5 (78): 5-15.
- [21] Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms, Curr. Med. Chem. 2013; 20 (36): 4640-5.
- [22] Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-dawley rats: the impacts of aqeous solubility, dose escalation, food and repeated dosing on oral bioavailability, J. Pharm. Sci. 2011; 100 (10): 4491-500.
- [23] Liu Yin MY, Wy X, Zeng M, Zhao Q, Keefe Liu DL. Resveratrol protects against age-associated infertility in mice, Hum. Reprod. 2013; 28 (3): 707-717.
- [24] MA Z, MOLAVI O, HADDADI A, LAI R, GOSSAGE RA, LAVASANIFAR A. Resveratrol analog trans 3,4,5,4’-tetramethoxystilbene(DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol, Cancer Chemother. Pharmacol. 2008; 63 (1): 27-35.
- [25] Mikstacka R, Rimando AM, Dutkiewicz Z, Stefański T, Sobiak S. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1, Bioorganic & Medicinal Chemistry 2012; 20 (17): 7117-5126.
- [26] Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T. Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults, Biochem. Pharmacol. 2007; 73: 550-560.
- [27] Olas B. Resweratrol jako dobroczyńca w profilaktyce chorób układu krążenia, Kosmos problemy nauk biologicznych 2006; 55 (2-3): 277-285.
- [28] Ovesna Z, Horvathova-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues, Neoplasma2005; 529 (6): 450-5.
- [29] Park E-J, Pezzuto JM. The pharmacology of resveratrol in animals and humans, BBA-Molecular Basis of Disease 2015; 1852 (6): 1071-1113.
- [30] PERVAIZ S. Resveratrol: from grapevines to mammalian biology, FASEB J. 2003; 17: 1975-1985.
- [31] Piotrowska H, Myszkowski K, Ziółkowska A, Kulcenty K, Wierzchowski M, Kaczmarek M, Murias M, Kwiatkowska-Borowczyk E, Jodynis-Liebert J. Resveratrol analogue 3,4,4’,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells, Toxicol. Apppl. Pharmacol. 2012; 263 (1): 53-60.
- [32] Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, RupareliaKC,Lamb JH, Farmer PB, Stanley LA, Burke MD. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B, Br. J. Cancer 2002; 86: 774-778.
- [33] Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, Reingold L, McKenna BJ, Christman GM. Resveratrol has anti-inflammatory and antifibrotic effects in the peptidoglycan- polysaccharide rat model of Crohn’s disease, Inflamm Bowel Dis. 2012; 18 (4): 613-23.
- [34] Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. Glycosylation of resveratrol protects it from enzymic oxidation, Biochem.J. 2003; 374: 157-163.
- [35] Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M. Synthesis and biological evaluation of resveratrol and analogs as apoptosis-inducing agents, J. Med. Chem. 2003; 46: 3546-3554.
- [36] Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its analog trans 3,4,5,4’-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells, Int. J. Cancer. 2005; 115 (2): 194-201.
- [37] Sale S, Verschoyle RD, Boocock D, Jones DJ.L, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, Gescher AJ. Pharmacokinetics in miceand growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4’-tetramethoxystilbene, Br. J. Cancer 2004; 90 (3): 736-744.
- [38] Schrauwen P, Timmers S. Can resveratrol help to maintain metabolic helath?, Proc. Nut.r Soc. 2014; 73 (2): 271-7.
- [39] Simoni D, Roberti M, Invidiata FP, Aiello E, Aiello S, Marchett P. Stilbene-based anticancer agents: Resveratrol analogues active toward HL-60 leukemic cells with a non-specific phas mechanism., Bioorg. Med. Chem. Lett. 2006; 16 (12): 3245-3248.
- [40] Singh N, Agrawal M, Dore S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models., ACS Chem. Neurosci. 2013; 4 (8): 1151-1162.
- [41] Sun X. Measurement and correlation of stability of trans-resveratrol in 11 solvents at T=(278,2, 288.2, 298.2 and 318.2), K. J. Chem. Thermodynamics 2008; 40: 735- 738.
- [42] Szaefer H, Cichocki M, Majchrzak-Celińska A. Nowe cytochromy P450 jako biomarkery i potencjalne cele oddziaływania w chemio prewencji i terapii nowotworów, PostepyHig. Med. Dosw. (online) 2013; 67: 709-718.
- [43] Udenigwe CC, Ramprasath VR, Aluko RE. Jones P.JH. Potential of resveratrol in anticancer and anti- -inflammatory therapy, Nutrition Reviews 2008; 66 (8): 445-454.
- [44] Waffo-Teguo P, Hawthorne ME, Cuendet M, Merillon JM, Kinghorn AD, Pezzuto JM, Mehta RG. Potential cancer - chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitisvinifera) cell cultures, Nutr. Cancer. 2001; 40: 173.
- [45] Wenezel E, Somoza V. Metabolism and bioavailability of trans-resveratrol, Mol.Nutr.Food Res. 2005; 49: 472-481.
- [46] You-QiuXue, Jin-Ming Di, Yun Luo, Ke-Jun Cheng, Xing Wei, Zhi Shi. Resveratrol oligomers for prevention and treatment of cancers, Oxid Med Cell Longev. 2014, Published online 2014 March 23.
- [47] Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate, Rapid Commun. Mass Spectrom. 2003; 17 (4): 307-13.
- [48] Zdrojewicz Z, Belowska-Bień K. Resweratrol - działanie i znaczenie kliniczne, Adv. Clin. Exp. Med. 2005; 14 (5): 1051-1056.